251 related articles for article (PubMed ID: 30657762)
1. BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.
Yogalingam G; Luu AR; Prill H; Lo MJ; Yip B; Holtzinger J; Christianson T; Aoyagi-Scharber M; Lawrence R; Crawford BE; LeBowitz JH
PLoS One; 2019; 14(1):e0207836. PubMed ID: 30657762
[TBL] [Abstract][Full Text] [Related]
2. Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B.
Grover A; Crippen-Harmon D; Nave L; Vincelette J; Wait JCM; Melton AC; Lawrence R; Brown JR; Webster KA; Yip BK; Baridon B; Vitelli C; Rigney S; Christianson TM; Tiger PMN; Lo MJ; Holtzinger J; Shaywitz AJ; Crawford BE; Fitzpatrick PA; LeBowitz JH; Bullens S; Aoyagi-Scharber M; Bunting S; O'Neill CA; Pinkstaff J; Bagri A
Drug Deliv Transl Res; 2020 Apr; 10(2):425-439. PubMed ID: 31942701
[TBL] [Abstract][Full Text] [Related]
3. Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B.
Prill H; Luu A; Yip B; Holtzinger J; Lo MJ; Christianson TM; Yogalingam G; Aoyagi-Scharber M; LeBowitz JH; Crawford BE; Lawrence R
Mol Ther Methods Clin Dev; 2019 Sep; 14():56-63. PubMed ID: 31309128
[TBL] [Abstract][Full Text] [Related]
4. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of α-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts.
Kan SH; Troitskaya LA; Sinow CS; Haitz K; Todd AK; Di Stefano A; Le SQ; Dickson PI; Tippin BL
Biochem J; 2014 Mar; 458(2):281-9. PubMed ID: 24266751
[TBL] [Abstract][Full Text] [Related]
6. Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome.
Kan SH; Elsharkawi I; Le SQ; Prill H; Mangini L; Cooper JD; Lawrence R; Sands MS; Crawford BE; Dickson PI
Mol Genet Metab; 2021 Jun; 133(2):185-192. PubMed ID: 33839004
[TBL] [Abstract][Full Text] [Related]
7. Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.
Aoyagi-Scharber M; Crippen-Harmon D; Lawrence R; Vincelette J; Yogalingam G; Prill H; Yip BK; Baridon B; Vitelli C; Lee A; Gorostiza O; Adintori EG; Minto WC; Van Vleet JL; Yates B; Rigney S; Christianson TM; Tiger PMN; Lo MJ; Holtzinger J; Fitzpatrick PA; LeBowitz JH; Bullens S; Crawford BE; Bunting S
Mol Ther Methods Clin Dev; 2017 Sep; 6():43-53. PubMed ID: 28664165
[TBL] [Abstract][Full Text] [Related]
8. Short-term enzyme replacement in the murine model of Sanfilippo syndrome type B.
Yu WH; Zhao KW; Ryazantsev S; Rozengurt N; Neufeld EF
Mol Genet Metab; 2000 Dec; 71(4):573-80. PubMed ID: 11136549
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of human recombinant and alpha-N-acetylglucosaminidase.
Weber B; Hopwood JJ; Yogalingam G
Protein Expr Purif; 2001 Mar; 21(2):251-9. PubMed ID: 11237686
[TBL] [Abstract][Full Text] [Related]
10. Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts.
Boado RJ; Lu JZ; Hui EK; Lin H; Pardridge WM
Mol Pharm; 2016 Apr; 13(4):1385-92. PubMed ID: 26910785
[TBL] [Abstract][Full Text] [Related]
11. Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB.
Meijer OLM; Welling L; Valstar MJ; Hoefsloot LH; Brüggenwirth HT; van der Ploeg AT; Ruijter GJG; Wagemans T; Wijburg FA; van Vlies N
J Inherit Metab Dis; 2016 May; 39(3):437-445. PubMed ID: 26907177
[TBL] [Abstract][Full Text] [Related]
12. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum.
Cressant A; Desmaris N; Verot L; Bréjot T; Froissart R; Vanier MT; Maire I; Heard JM
J Neurosci; 2004 Nov; 24(45):10229-39. PubMed ID: 15537895
[TBL] [Abstract][Full Text] [Related]
13. Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency.
Lotfi P; Tse DY; Di Ronza A; Seymour ML; Martano G; Cooper JD; Pereira FA; Passafaro M; Wu SM; Sardiello M
Autophagy; 2018; 14(8):1419-1434. PubMed ID: 29916295
[TBL] [Abstract][Full Text] [Related]
14. Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells.
Huang W; Cheng YS; Yang S; Swaroop M; Xu M; Huang W; Zheng W
Exp Cell Res; 2021 Oct; 407(1):112785. PubMed ID: 34411609
[TBL] [Abstract][Full Text] [Related]
15. Processing of mutant N-acetyl-α-glucosaminidase in mucopolysaccharidosis type IIIB fibroblasts cultured at low temperature.
Meijer OLM; Te Brinke H; Ofman R; IJlst L; Wijburg FA; van Vlies N
Mol Genet Metab; 2017 Sep; 122(1-2):100-106. PubMed ID: 28751108
[TBL] [Abstract][Full Text] [Related]
16. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
[TBL] [Abstract][Full Text] [Related]
17.
De Pasquale V; Esposito A; Scerra G; Scarcella M; Ciampa M; Luongo A; D'Alonzo D; Guaragna A; D'Agostino M; Pavone LM
J Med Chem; 2023 Feb; 66(3):1790-1808. PubMed ID: 36696678
[TBL] [Abstract][Full Text] [Related]
18. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase.
Li HH; Yu WH; Rozengurt N; Zhao HZ; Lyons KM; Anagnostaras S; Fanselow MS; Suzuki K; Vanier MT; Neufeld EF
Proc Natl Acad Sci U S A; 1999 Dec; 96(25):14505-10. PubMed ID: 10588735
[TBL] [Abstract][Full Text] [Related]
19. Structural characterization of the α-N-acetylglucosaminidase, a key enzyme in the pathogenesis of Sanfilippo syndrome B.
Birrane G; Dassier AL; Romashko A; Lundberg D; Holmes K; Cottle T; Norton AW; Zhang B; Concino MF; Meiyappan M
J Struct Biol; 2019 Mar; 205(3):65-71. PubMed ID: 30802506
[TBL] [Abstract][Full Text] [Related]
20. Mouse model of Sanfilippo syndrome type B: relation of phenotypic features to background strain.
Gografe SI; Garbuzova-Davis S; Willing AE; Haas K; Chamizo W; Sanberg PR
Comp Med; 2003 Dec; 53(6):622-32. PubMed ID: 14727810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
